There has been a spate of drug companies settling patent litigation recently.
Progenics Pharmaceuticals, Valeant Pharmaceuticals, Salix Pharmaceuticals, and Wyeth LLC settled two patent infringement lawsuits with Actavis over its proposed generic versions of Relistor products. Relistor treats constipation caused by narcotic pain medications. Actavis admitted the patents are valid and enforceable and it was granted a limited license to the patents. Full-year 2017 net worldwide sales of Relistor were $73.1 million.
Meanwhile, Gilead Sciences Inc. and Mylan Pharmaceuticals Inc. told the U.S. District Court for the District of Delaware they were about two weeks away from finalizing a settlement deal over infringement litigation relating to Mylan’s proposed generic copy of Gilead’s HIV-treatment booster Tybost.
Pfizer Inc. and Aurobindo Pharma USA Inc. voluntarily ended litigation over Aurobindo’s planned copycat of Pfizer’s drug Tikosyn, which treats abnormal heart beats. Other companies’ generic versions of the drug have been on the market since 2016.
Tikosyn was one of the drugs for which a charitable organization set up by Pfizer paid Medicare patients’ copayments. Earlier this year, Pfizer agreed to pay $23.8 million to settle allegations it violated the federal False Claims Act by paying the copayments for Tikosyn and for the kidney cancer drugs Sutent and Inlyta.
Pfizer has a separate program in which it offers drugs for free to qualifying patients, which is legal. The Justice Department alleged, however, that Pfizer worked with a third-party pharmacy to direct some of those patients to the foundation’s free copay program, so that it could file claims to Medicare for the drugs, and enhance its profits.
Pfizer raised the price of Tikosyn 44 percent during the time it sent patients to its foundation and while claims for the prescription drugs were sent to Medicare.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)